HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment

Publication date: Available online 4 May 2018

Source: Seminars in Oncology

Author(s): Iraldo Bello-Rivero, Yanelda Garcia-Vega, Yaquelin Duncan-Roberts, Dania Vazquez-Blomquistc, Hector Santana-Milian, Vladimir Besada-Perez, Margarita Rios-Cabrera

Abstract

The rational combination of recombinant IFN-α2b and IFN-γ resulted in a new formulation of interferons (HeberFERON) with improved pharmacodynamics. In basal cell carcinomas HeberFERON produces a more rapid antitumor effect and results in a larger number of complete responses. In patients with glioblastoma multiforme, the administration of HeberFERON after surgery and radiotherapy results in an estimated overall survival of 19 months. Patients with stage III or IV renal cell carcinoma also appear to benefit from the intravenous administration of HeberFERON, with prolongation of survival and good quality of live. HeberFERON offers a promising alternative formulation of interferons for the treatment of cancer with a very favorable safety profile.

https://ift.tt/2ITFuM0